HW-071021 / Humanwell Healthcare - LARVOL DELTA

Discovery of a highly potent and efficacious SOS1 inhibitor targeting KRAS-driven cancers (AACR 2025) - "These data support the clinical utility of HW071021 as a single agent or combination partner of Osimertinib for the treatment of human Kras-driven cancers. IND application in China has been approved in September."

Lung Cancer • Oncology • Solid Tumor • EGFR • KRAS

HW071021 Monotherapy in Patients with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=76 | Not yet recruiting | Sponsor: Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

Monotherapy • New P1 trial • Oncology • Solid Tumor